Cetuximab alleviates neuropathic pain despite tumour progression

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Kersten, Christian ^a   Cameron, Marte Grønlie ^a  

^a Hospital of Southern Norway Kristiansand   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CAPECITABINE; CARBAMAZEPINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; IRINOTECAN; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; OXYGEN; PARACETAMOL; PREDNISOLONE; PREGABALIN;

ACUPUNCTURE; ADULT; ANALGESIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; ELECTROMYOGRAPHY; ELECTRONEUROGRAPHY; FOOT PAIN; HUMAN; HYPERBARIC OXYGEN; LUNG METASTASIS; MALE; NEUROPATHIC PAIN; PLACEBO EFFECT; PRIORITY JOURNAL; RECTUM CANCER; RECTUM RESECTION; REOPERATION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 84864577556     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.12.2011.5374     Document Type: Article

References (27)

1. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain 2011;152:2204-5.
2. Boureau F, Doubrère JF, Luu M. Study of verbal description in neuropathic pain. Pain 1990;42:145-52.
3. Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002;18:343-9.
4. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81.
5. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178-82.
6. Dieleman JP, Kerklaan J, Huygen FJ, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008;137:681-8.
7. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007;10:1361-8.
8. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19.
9. Ji RR. Mitogen-activated protein kinases as potential targets for pain killers. Curr Opin Investig Drugs 2004;5:71-5.
10. Ji RR, Gereau RW, Malcangio M, et al. MAP kinase and pain. Brain Res Rev 2009;60:135-48.
11. Yasuda S, Sugiura H, Tanaka H, et al. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Cent Nerv Syst Agents Med Chem 2011;11:45-59.
12. Calvo M, Zhu N, Grist J, et al. Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway. Glia 2011;59:554-68.
13. Anand P, Shenoy R, Palmer JE, et al. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 2011;15:1040-8.
14. Martin YB, Herradón G, Ezquerra L. Uncovering new pharmacological targets to treat neuropathic pain by understanding how the organism reacts to nerve injury. Curr Pharm Des 2011;17:434-48.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
16. Mesía R, Palmero R, Cos M, et al. Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report. Head Neck Oncol 2010;2:3.
17. Vincenzi B, Zoccoli A, Pantano F, et al. Cetuximab: from bench to bedside. Curr Cancer Drug Targets 2010;10:80-95.
18. Holt K. Common side effects and interactions of colorectal cancer therapeutic agents. J Pract Nurs 2011;61:7-20.
19. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
20. Nautiyal J, Rishi AK, Majumdar AP. Emerging therapies in gastrointestinal cancers. World J Gastroenterol 2006;12:7440-50.
21. Schamel WW, Dick TP. Signal transduction: specificity of growth factors explained by parallel distributed processing. Med Hypotheses 1996;47:249-55.
22. Ramanathan RK. Alternative dosing schedules for cetuximab: a role for biweekly administration? Clin Colorectal Cancer 2008;7:364-8.
23. Liu B, Neufeld AH. Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. J Neurosci Res 2007;85:3523-9.
24. Carroll SL, Miller ML, Frohnert PW, et al. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 1997;17:1642-59.
25. Andres C, Meyer S, Dina OA, et al. Quantitative automated microscopy (QuAM) elucidates growth factor specific signalling in pain sensitization. Mol Pain 2010;6:98.
26. Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5-fluouracil/folinate/oxaliplatin given continously or intermittently with or witout cetuximab: the NORDIC VII study (NCT00145314). Ann Oncol. 2010;21(Suppl 8):viii1-2.
27. Maughan TS, Adams RA, Smith CG, et al.; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14.